https://gnqin.com/gnq-insilicos-ai-driven-digital-twins-platform-shows-promising-results-in-simulating-effects-of-a-drug-on-synthesized-digital-twins/2025-09-12T03:11:04+00:00https://gnqin.com/gnq-insilico-announces-collaboration-with-fortune-100-company-to-develop-next-generation-clinical-trial-platform/2025-09-10T20:05:03+00:00https://gnqin.com/gnq-unveils-ai-powered-platform-prototype-delivering-128-auc-improvement-in-personalized-clomiphene-dosing-optimization/2025-09-11T14:04:32+00:00https://gnqin.com/gnq-presents-at-quantum-rising-conference-alongside-deloitte-ibm-quantum/2025-09-11T14:06:46+00:00https://gnqin.com/gnq-insilico-launches-revolutionary-ai-driven-assessment-platform-to-transform-precision-medicine-and-drug-development/2025-09-17T18:57:30+00:00https://gnqin.com/gnq-insilico-unveils-multi-pathway-therapeutic-formulation-for-als-leveraging-proprietary-drug-assessment-platform/2025-09-11T14:10:25+00:00https://gnqin.com/gnqs-drug-assessment-platform-enhances-non-small-cell-lung-cancer-treatment-by-extending-efficacy-beyond-universal-resistance-barrier/2025-09-11T14:12:04+00:00https://gnqin.com/gnq-insilico-secures-mindlab-an-award-winning-pharma-company-as-a-client-for-its-drug-assessment-platform/2025-10-30T20:24:39+00:00https://gnqin.com/fda-shifts-60-year-default-one-pivotal-clinical-trial-is-now-the-default-for-drug-approval-replacing-the-two-trial-requirement-this-shift-rewards-what-gnq-was-built-to-deliver-mechanistic/2026-03-03T09:51:45+00:00https://gnqin.com/gnq-insilico-inc-to-go-public-through-business-combination-with-ib-acquisition-corp-nasdaq-ibac/2026-03-20T00:19:06+00:00https://gnqin.com/gnq-insilico-plans-to-accelerate-precision-medicine-and-clinical-ai-adoption-across-drug-development-and-patient-care/2026-04-17T04:28:56+00:00